|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
3
|
Jelic S: Hepatocellular carcinoma: ESMO
clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 20(Suppl 4): 41–45. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lai EC, Fan ST, Lo CM, Chu KM, Liu CL and
Wong J: Hepatic resection for hepatocellular carcinoma. An audit of
343 patients. Ann Surg. 221:291–298. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
No authors listed. A comparison of
lipiodol chemoembolization and conservative treatment for
unresectable hepatocellular carcinoma. Groupe d’Etude et de
Traitement du Carcinome Hepatocellulaire. N Engl J Med.
332:1256–1261. 1995.
|
|
6
|
Schwartz JD and Beutler AS: Therapy for
unresectable hepatocellular carcinoma: review of the randomized
clinical trials-II: systemic and local non-embolization-based
therapies in unresectable and advanced hepatocellular carcinoma.
Anticancer Drugs. 15:439–452. 2004. View Article : Google Scholar
|
|
7
|
Biswas C: Tumor cell stimulation of
collagenase production by fibroblasts. Biochem Biophys Res Commun.
109:1026–1034. 1982. View Article : Google Scholar
|
|
8
|
Biswas C, Zhang Y, DeCastro R, et al: The
human tumor cell-derived collagenase stimulatory factor (renamed
EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res.
55:434–439. 1995.PubMed/NCBI
|
|
9
|
Philp NJ, Ochrietor JD, Rudoy C, Muramatsu
T and Linser PJ: Loss of MCT1, MCT3, and MCT4 expression in the
retinal pigment epithelium and neural retina of the
5A11/basigin-null mouse. Invest Ophthalmol Vis Sci. 44:1305–1311.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo H, Zucker S, Gordon MK, Toole BP and
Biswas C: Stimulation of matrix metalloproteinase production by
recombinant extracellular matrix metalloproteinase inducer from
transfected Chinese hamster ovary cells. J Biol Chem. 272:24–27.
1997. View Article : Google Scholar
|
|
11
|
Zhu S, Li Y, Mi L, et al: Clinical impact
of HAb18G/CD147 expression in esophageal squamous cell carcinoma.
Dig Dis Sci. 56:3569–3576. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhong WD, Liang YX, Lin SX, et al:
Expression of CD147 is associated with prostate cancer progression.
Int J Cancer. 130:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu F, Cui L, Zhang Y, et al: Expression
of HAb18G is associated with tumor progression and prognosis of
breast carcinoma. Breast Cancer Res Treat. 124:677–688. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He HC, Han ZD, Dai QS, et al: Expression
and significance of CD147 protein in prostate cancer. Zhonghua Yi
Xue Za Zhi. 89:1844–1846. 2009.(In Chinese).
|
|
15
|
Xu J, Xu HY, Zhang Q, et al: HAb18G/CD147
functions in invasion and metastasis of hepatocellular carcinoma.
Mol Cancer Res. 5:605–614. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Redondo P, Lloret P, Idoate M and Inoges
S: Expression and serum levels of MMP-2 and MMP-9 during human
melanoma progression. Clin Exp Dermatol. 30:541–545. 2005.
View Article : Google Scholar
|
|
17
|
Kawamura K, Kamiya N, Suyama T, et al: In
situ gelatinolytic activity correlates with tumor progression and
prognosis in patients with bladder cancer. J Urol. 172:1480–1484.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun J and Hemler ME: Regulation of MMP-1
and MMP-2 production through CD147/extracellular matrix
metalloproteinase inducer interactions. Cancer Res. 61:2276–2281.
2001.PubMed/NCBI
|
|
19
|
Xu J, Shen ZY, Chen XG, et al: A
randomized controlled trial of Licartin for preventing hepatoma
recurrence after liver transplantation. Hepatology. 45:269–276.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanekura T, Chen X and Kanzaki T: Basigin
(CD147) is expressed on melanoma cells and induces tumor cell
invasion by stimulating production of matrix metalloproteinases by
fibroblasts. Int J Cancer. 99:520–528. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Llovet JM, Real MI, Montana X, et al:
Arterial embolisation or chemoembolisation versus symptomatic
treatment in patients with unresectable hepatocellular carcinoma: a
randomised controlled trial. Lancet. 359:1734–1739. 2002.
View Article : Google Scholar
|
|
22
|
Hansler J, Neureiter D, Wasserburger M, et
al: Percutaneous US-guided radiofrequency ablation with perfused
needle applicators: improved survival with the VX2 tumor model in
rabbits. Radiology. 230:169–174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoon CJ, Chung JW, Park JH, et al:
Transcatheter arterial chemoembolization with paclitaxel-lipiodol
solution in rabbit VX2 liver tumor. Radiology. 229:126–131. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
25
|
Zhang Z, Bian H, Feng Q, et al:
Biodistribution and localization of iodine-131-labeled metuximab in
patients with hepatocellular carcinoma. Cancer Biol Ther.
5:318–322. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamaguchi R, Yano H, Iemura A, Ogasawara
S, Haramaki M and Kojiro M: Expression of vascular endothelial
growth factor in human hepatocellular carcinoma. Hepatology.
28:68–77. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamaguchi S, Tohnai I, Ito A, et al:
Selective hyperthermia using magnetoliposomes to target cervical
lymph node metastasis in a rabbit tongue tumor model. Cancer Sci.
94:834–839. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marelli L, Stigliano R, Triantos C, et al:
Transarterial therapy for hepatocellular carcinoma: which technique
is more effective? A systematic review of cohort and randomized
studies. Cardiovasc Intervent Radiol. 30:6–25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Biolato M, Marrone G, Racco S, et al:
Transarterial chemoembolization (TACE) for unresectable HCC: a new
life begins? Eur Rev Med Pharmacol Sci. 14:356–362. 2010.PubMed/NCBI
|
|
31
|
Yang Y, Lu N, Zhou J, Chen ZN and Zhu P:
Cyclophilin A up-regulates MMP-9 expression and adhesion of
monocytes/macrophages via CD147 signalling pathway in rheumatoid
arthritis. Rheumatology. 47:1299–1310. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dai JY, Dou KF, Wang CH, et al: The
interaction of HAb18G/CD147 with integrin alpha6beta1 and its
implications for the invasion potential of human hepatoma cells.
BMC Cancer. 9:3372009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou J, Zhu P, Jiang JL, et al:
Involvement of CD147 in overexpression of MMP-2 and MMP-9 and
enhancement of invasive potential of PMA-differentiated THP-1. BMC
Cell Biol. 6:252005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stewart CJ and Crook ML: CD147 (EMMPRIN)
and matrix metalloproteinase-2 expression in uterine endometrioid
adenocarcinoma. Pathol Res Pract. 207:30–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Afonso J, Longatto-Filho A, Baltazar F, et
al: CD147 overexpression allows an accurate discrimination of
bladder cancer patients’ prognosis. Eur J Surg Oncol. 37:811–817.
2011.PubMed/NCBI
|
|
36
|
Voigt H, Vetter-Kauczok CS, Schrama D,
Hofmann UB, Becker JC and Houben R: CD147 impacts angiogenesis and
metastasis formation. Cancer Invest. 27:329–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
